Jason Broderick

Articles

TAS-102 Plus Bevacizumab Is Potential New Option in Refractory mCRC

March 12th 2020

The addition of bevacizumab to TAS-102 (trifluridine/tipiracil; Lonsurf) reduced the risk of disease progression or death compared with TAS-102 alone in patients with chemorefractory metastatic colorectal cancer.

Cediranib/Olaparib Combo Falls Short in Phase III Relapsed Ovarian Cancer Trial

March 12th 2020

Cediranib plus olaparib did not lead to a statistically significant improvement in progression-free survival compared with platinum-based chemotherapy in patients with platinum-sensitive relapsed ovarian cancer.

Frontline Venetoclax/Obinutuzumab Approved in Europe in CLL

March 12th 2020

The European Commission has approved a fixed-dose combination of venetoclax and obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia.

Cirmtuzumab/Ibrutinib Combo Active in Mantle Cell Lymphoma

March 12th 2020

Combination therapy with cirmtuzumab and ibrutinib induced a 50% complete response rate in the phase I/II CIRLL study.

Zanubrutinib Highly Active in Non-Hodgkin Lymphoma

December 10th 2017

The investigational BTK inhibitor zanubrutinib (BGB-3111) demonstrated promising clinical activity in patients with non-Hodgkin lymphoma.

FDA Approves Dasatinib for Pediatric Ph+ Chronic Phase CML

November 10th 2017

The FDA has approved dasatinib (Sprycel) for the treatment of pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.

Pembrolizumab Approved in Europe for Urothelial Carcinoma

September 6th 2017

The European Commission has approved pembrolizumab (Keytruda) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy, or who are not eligible for cisplatin-containing chemotherapy.

FDA Approval Sought for Frontline Cabozantinib in RCC

August 16th 2017

A supplemental new drug application has been submitted to the FDA for cabozantinib for previously untreated patients with advanced renal cell carcinoma.

Immunotherapy Gains Frontline Foothold in NSCLC

May 29th 2017

Less than 2 years after checkpoint blockade immunotherapy first became available for patients with non-small cell lung cancer, the PD-1 inhibitor pembrolizumab is poised to reshape the treatment paradigm for previously untreated individuals without molecular mutations.

Expert Discusses Value of Venetoclax After BCR Inhibition in CLL

February 3rd 2017

Jeffrey Jones, MD, discusses promising early data for venetoclax in chronic lymphocytic leukemia after progression on BCR-pathway inhibitors, as well as the next steps with the research.

ASCO Selects Dramatic Improvement in CLL Care as 'Cancer Advance of the Year'

January 20th 2015

ASCO named the vastly improved outlook for patients with chronic lymphocytic leukemia as its inaugural "Cancer Advance of the Year."

NCCN 2011 Guidelines for Breast Cancer: Yes on Avastin, No on CYP2D6

March 21st 2011

As the Avastin (bevacizumab) drama continues at the FDA, the National Comprehensive Cancer Network (NCCN) has weighed in.

Oncology Gadget Watch: April 27, 2010

April 27th 2010

Three hot gadgets for Oncologists.

Judge Rules Myriad Cannot Patent BRCA1 and BRCA2-Genes

April 4th 2010

A US district court invalidated 7 of 23 of Myriad Genetics, Inc's patents on the BRCA1 and BRCA2 genes, which confer an increased risk of developing breast, ovarian, and prostate cancers.